Gilde Healthcare appoints Jan Willem Bakker as Head of Investor Relations - Gilde Healthcare

Gilde Healthcare appoints Jan Willem Bakker as Head of Investor Relations

September 2, 2024
Utrecht (the Netherlands)

Gilde Healthcare, the transatlantic specialist investment firm, is pleased to announce the addition of Jan Willem Bakker to its team as Partner & Head of Investor Relations.

Jan Willem will focus on Gilde Healthcare’s investor relations activities and contribute to the firm’s capital raising, marketing and communications efforts. With over 20 years of experience in client facing roles in financial services he brings vast experience to benefit existing and new LPs of the Gilde Healthcare platform. “We are pleased to welcome Jan Willem to our Investor Relations and Fundraising team,” said Pieter van der Meer, Managing Partner of Gilde Healthcare. “His extensive track record with institutional investors both as an LP and GP, strong industry relationships, and entrepreneurial mindset will help in strengthening our fundraising strategy and investor relationships. He will be instrumental in the foreseen expansion of our fund platform with impactful private equity strategies.”

Prior to joining Gilde Healthcare, Jan Willem was a partner at Prime Ventures having previously held senior roles at Arcano Partners and Adveq Management AG (now Schroders Capital), during his time at Adveq Jan Willem was a board member of the Dutch Private Equity association (NVP). He began his career in financial services at Kas Bank N.V. “I am very happy to join Gilde Healthcare’s ambitious team and contribute to building out its impactful platform. I look forward to collaborating with existing and prospective investors, investment and finance teams on delivering innovative and successful investment solutions to benefit a range of stakeholders.” said Jan Willem.

About Gilde Healthcare
Gilde Healthcare is a transatlantic specialist investment firm managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare company Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of...
April 22, 2025

Gilde Healthcare company SynOx Therapeutics announces Board Chair transition to align with advancing Regulatory and Commercialization Strategy

SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today announced the execution of a planned and orderly transition of its board chair position. Philip Astley-Sparke...
April 1, 2025

Gilde Healthcare company SpliceBio announces first patient dosed in Phase 1/2 ASTRA study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations SB-007 is the first dual AAV gene therapy in clinical development for Stargardt disease   SpliceBio,...
March 13, 2025